Browsing Tag: Funding Accelerated for Specific Treatments

Takeaways:  Ontario’s reimbursement of BRAFTOVI is a meaningful win for Pfizer and a strong signal for precision oncology adoption in Canada. It should accelerate uptake in a biomarker-defined me...